Частина V. Оптимальне використання бендамустину при гематологічних захворюваннях: рекомендації по  лікуванню Міжнародної Погоджувальної Комісії – оновлення

Bruce D. Cheson, a , * Wolfram Brugger, b Gandhi Damaj, c Martin Dreyling, d Brad Kahl, e Eva Kimby, f Michinori Ogura,g Eckhart Weidmann, h Clemens-Martin Wendtner, i and Pier Luigi Zinzani j

Інформація про авторів статті

LEUKEMIA & LYMPHOMA, 2016 VOL. 57, NO. 4, 766–782 
Journal List Taylor & Francis Open Select PMC4840280

Частина V (Частину ІV див. http://vista-mediclub.com/oncology-news-ua/1713-chastina-iv-optimalne-vikoristannja-bendamustinu-pri-gematologichnih-zahvorjuvannjah-rekomendacii-po-likuvannju-mizhnarodnoi-pogodzhuvalnoi-komisii-onovlennja)

Скорочення:

(CLL) chronic lymphocytic leukemia - хронічний лімфоцитарний лейкоз (ХЛЛ)
(NHL) non-Hodgkin's lymphoma – негоджкінська лімфома (НХЛ)
(MM) multiple myeloma - множинна мієлома
(PFS) progression free survival - виживаність без прогресування
(BR) – бендамустин+ритуксимаб
(ORR) overall response rate - загальний відсоток відповіді
(CR) complete response - повна відповідь
(FCR) - флударабин + циклофосфан + рітуксімаб
(StiL) Study Group indolent Lymphomas - Дослідна група лімфом
(R-CHOP) - ритуксимаб / циклофосфамід / доксорубіцин / вінкристин / преднізолон
(MCL) mantle cell lymphoma – мантійно-клітинна лімфома
(OS) overall survival - загальна виживаність

bendamustinn

Інші індолентні лімфоми

Терапія вибору при лімфомах маргінальної зони (MZL), макроглобулінемії Вальденстрема (WM) і пухлин, що розвиваються з лімфоїдної тканини, асоційованих із слизовими оболонками (MALT) –лімфоми

У дослідженні StiL NHL-1 2003 BR комбінація не поступалася R-СНОР в групі хворих з MZL (n= 67) і перевершувала по ефективності в групі WM (n = 41) згідно з показником PFS. Загальні показники CR були вище в групі BR (40%) у порівнянні з групою R-CHOP (30%). Щодо оновлених показників виживаності в рамках цього протоколу, позитивні результати на користь BR зберігаються при медіані спостереження до 87 місяців. Медіана OS у пацієнтів з WM і MZL ще не досягнута і достовірно поки не відрізняється в цих групах.
У дослідженні BRIGHT, BR був настільки ж ефективний, як і R-CHOP чи R-CVP у пацієнтів з MZL (п = 46) з позиції показника CR, але з, можливо, кращим терапевтичним індексом. Показник CR/ОRR був 20%/92% в групі BR і 24%/71% в групі R-CHOP/R-СVP, відповідно.
ФАЗА II нерандомізованого дослідження, нещодавно проведеного в групі 58 пацієнтів з нелікованими CD20 + MALT лімфомами (середній вік = 62 років; III/IV стадія = 34 %). Після трьох циклів ОRR був 100% з 76% CR/Cru. Після трьох циклів була виділена група пацієнтів з частковою відповіддю на терапію (PR), 93% із якої після шести циклів перерозподілилися в групу з повною відповіддю на терапію (CR); 77% пацієнтів було потрібно тільки чотири цикли для досягнення CR.

Бендамустин при рецидивах/рефрактерних формах

Ефективність бендамустина була також досліджена в групі пацієнтів, які отримували ритуксимаб на попередніх етапах і в групі ритуксимаб-рефрактерних пацієнтів з фолікулярними, індолентними В-клітинними лімфомами. У дослідженні American кілька пацієнтів з MZL отримували монотерапію бендамустином. ORR варіювала в межах 71-86%, при цьому показник CR/CRu - в межах 43% у пацієнтів з MZL. У декілька інших досліджень за участю ритуксимаб-рефрактерних пацієнтів також були включені пацієнти з iNHL (зокрема пацієнтів з FL), які показали вражаючі результати, хоча число таких пацієнтів в цих дослідженнях було зовсім невеликим. Єдине рандомізоване дослідження (III фаза) NHL-2 2003 в популяції хворих, які вже отримали курс терапії на попередньому етапі, у яких BR порівнювалися з флударабіном плюс ритуксімаб (FR: флударабін 25 мг / м2 1-3 дні). Показники PFS за 18 місяців в групі BR були вищими. Оновлені показники OS продемонстрували суттєву різницю в групі BR (110 місяців) в порівнянні з FR (49 місяців; п = 0,0125).
Останнім часом також було доведено, що ефективність BR досить висока і в популяції попередньо пролікованих пацієнтів (n = 14) з не шлунковими MALT лімфомами за даними ретроспективного аналізу. Показник CR - 71%, показник PR -21%. Лікування зазвичай досить добре переноситься. При медіані спостереження 23 місяці, лише у одного пацієнта спостерігався рецидив захворювання.

Рекомендації погоджувальної групи - інші індолентні лімфоми

BR може розглядатися у якості терапії першої лінії у пацієнтів з WL і MZL;
• Чотири цикли BR слід вважати достатнім для пацієнтів, які отримували попередню терапію ритуксимабом;
Монотерапія бендамустином може застосовуватися в групі ритуксимаб-рефрактерних пацієнтів.

З медичною інструкцією Бендамустин-Віста можна ознайомитись за посиланням http://vista-mediclub.com/preparaty-vista/1650-bendamustinvista-bendamustinvista.

Інформацію про наявність в аптеках України і ціну можна дізнатись на http://medbrowse.com.ua/bendamustin-vista-cena/ukraina

Інформація про авторів статті

aLombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA
bSchwarzwald-Baar Clinic, University of Freiburg, Villingen-Schwenningen, Germany
cUniversity Hospital, University of Basse-Normandie, Caen, France
dMedical Clinic, University Hospital of Munich, Munich, Germany
eUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA
fCenter for Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
gDepartment of Hematology, Tokai Central Hospital, Gifu, Japan
hDepartment of Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany
iKlinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany
jInstitute of Hematology, University of Bologna, Bologna, Italy
CONTACT Professor Bruce D. Cheson ; Email: ude.nwotegroeg@4cdb, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road, NW, Washington, DC, USA

References

    Ozegowski WKD. IMET, 3393 (-[1-methyl-5-bis-(b-chloroethyl)-amino-benzimidazolyl-(2)]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds. Zbl Pharm Pharmakother Lab. 1971;110:1013–1019.
    Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378–4384. [PubMed]
    Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204–210. [PubMed]
    Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106–114. [PMC free article] [PubMed]
    Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010;10:21–27. [PubMed]
    Leoni L, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309–317. [PubMed]
    Gandhi V. Metabolism and mechanisms of action of bendamustine rationales for combination therapies. Semin Oncol. 2002;29(Suppl. 13):4–11. [PubMed]
    Kath R, Blumenstengel K, Fricke HJ, et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 2001;127:48–54. [PubMed]
    Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomas. Anticancer Drugs. 2001;12:725–729. [PubMed]
    Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol. 2007;59:759–70. [PubMed]
    http://www.treanda.com/pdf/TREANDA_final_PI.pdf
    Preiss R, Teichert J, Pönisch W, et al. Pharmacokinetics and toxicity profile of bendamustine in myeloma patients with end-stage renal disease. Hematology J. 2003;4(Suppl. 1)
    McCloskey JK, Broome CM, Cheson BD. Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment. Clin Adv Hematol Oncol. 2013;11:184–188. [PubMed]
    Eichhorst B, Fink AM, Busch R. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood. 2014;124:19.
    Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica. 2005;90:1357–1364. [PubMed]
    Lissitchkov T, Arnaudov G, Peytchev D, et al. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol. 2006;132:99–104. [PubMed]
    Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559–3566. [PubMed]
    Offner F, Panagiotidis P, Afanasyev B, et al. Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: initial results of the phase II study OMB115991. Int Workshop CLL. 2013;4:29.
    Cortelezzi A, Sciume M, Liberati AM, et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia. 2014;28:642–648. [PubMed]
    Brown JR, O'Brien S, Kingsley D. Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase 1b Galton Trial (GAO4779g) [abstract]. Blood (Suppl) 2013;122:523.
    Ujjani C, Ramzi P, Gehan E, et al. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015:915–920. [PubMed]
    Brown JR, Barrientos JC, Barr PM, et al. Ibrutinib In combination with bendamustine and rituximab Is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study. Blood. 2013;122:525.
    Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210. [PubMed]
    Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209–3216. [PubMed]
    Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944–2952. [PMC free article] [PubMed]
    Salar A, Domingo-Domenech E, Panizo E, et al. Final results of a multicenter phase II trial with bendamustine and rituximab as first line treatment for patients with MALT lymphoma (MALT-2008-01). Blood. 2012;120:3691.
    Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22:1839–1844. [PubMed]
    Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1285–1289. [PubMed]
    Ohmachi K, Niitsu N, Uchida T. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol . 2013;31:2103–2109. [PubMed]
    Vacirca JL, Acs PI, Tabbara IA, et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014;93:403–409. [PMC free article] [PubMed]
    Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31:104–110. [PubMed]
    Zaja F, Baldini L, Ferreri AJ, et al. Bendamustine salvage therapy for T cell neoplasms. Ann Hematol. 2013;92:1249–1254. [PubMed]
    Weide R, Feiten S, Friesenhahn V, et al. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leuk Lymphoma. 2013;54:1640–1646. [PubMed]
    Rummel MJ, Maschmeyer G, Ganser A, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL) – 7 year updated results from the StiL NHL1 study [abstract]. Blood (Suppl) 2014;124:4407.
    Kuruvilla J, Assouline S, Hodgson D, et al. A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board. Clin Lymphoma Myeloma Leuk. 2015;15:59–74. [PubMed]
    Flinn IW, van RC, Kahl BS. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright Study. Blood. 2012;120:902.
    Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383–3389. [PubMed]
    Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. Oncologist. 2013;18:954–964. [PMC free article] [PubMed]
    Rummel MJ, Kaiser T, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL 2-2003 on behalf of the STIL (Study Group Indolent Lymphomas, Germany). Blood. 2010;116:856.
    Rummel MJ, Balsar C, Kaiser U, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent, or mantle cell lymphomas – 8-year follow-up results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2014;124:145.
    Kiesewetter B, Mayerhoefer ME, Lukas J, et al. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Ann Hematol. 2014;93:249–253. [PubMed]
    Ogura M, Ando K, Taniwaki M, et al. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Cancer Sci. 2011;102:1687–1692. [PubMed]
    Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473–4479. [PubMed]
    Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma. 2007;48:1299–1306. [PubMed]
    Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–1449. [PubMed]
    Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807–2812. [PMC free article] [PubMed]
    Jerkeman M, Kolstad A, Laurell A, et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. Blood. 2011;118:2700.
    Zaja F, Ferrero S, Stelitano C, et al. Rituximab, lenalidomide, bendamustine second line therapy in mantel cell lymphoma: a phase II study of the fondazione Italiana linfomi (FIL). Hematological Oncology. 2015;33(Suppl. 1)
    Hess G, Keller U, Scholz CW. Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia. 2015;29:1695–1701. [PubMed]
    Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–3695. [PMC free article] [PubMed]
    Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829. [PubMed]
    Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13:716–723. [PubMed]
    Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24:2892–2897. [PMC free article] [PubMed]
    Cheson BD, Crawford J. A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas. Br J Haematol. 2015;169:528–533. [PubMed]
    Savage KJ. Therapies for peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2011;2011:515–524. [PubMed]
    Rosenstein LJ, Link BK. Optimizing chemotherapeutic strategies for peripheral T-cell lymphomas. Clin Lymphoma Myeloma. 2008;8(Suppl. 5):S180–S186. [PubMed]
    Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–3425. [PubMed]
    Herbaux C, Genet P, Bouabdallah K, et al. Bendamustine is effective in T-Cell prolymphocytic leukaemia. Br J Haematol. 2015;168:916–919. [PubMed]
    Anastasia A, Carlo-Stella C, Corradini P, et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014;166:140–142. [PubMed]
    Corazzelli G, Angrilli F, D'Arco A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207–215. [PubMed]
    Ghesquieres H, Stamatoullas A, Casasnovas O, et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma. 2013;54:2399–2404. [PubMed]
    Moskowitz AJ, Hamlin PA, Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31:456–460. [PMC free article] [PubMed]
    Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30:2183–2189. [PMC free article] [PubMed]
    Zinzani PL, Derenzini E, Pellegrini C, et al. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. Br J Haematol. 2013;163:681–683. [PubMed]
    Zinzani PL, Vitolo U, Viviani S, et al. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience with 27 patients. Clin Lymphoma Myeloma Leuk. 2015;1:404–448. [PubMed]
    LaCasce A, Sawas A, Bociek R, et al. A phase 1/2 single-srm, open-label study to evaluate the safety and efficacy of brentuximab vedotin in combination with bendamustine for patients with Hodgkin Lymphoma in the first salvage setting: interim results. Biol Blood Marrow Transplant. 2014;20:S161.
    Pratt G, Bowcock S, Lai M, et al. United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. Int J Lab Hematol. 2014;36:20–28. [PubMed]
    Pönisch W, Mitrou PS, Merkle K. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone – a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132:205–212. [PubMed]
    Pönisch W, Holzvogt B, Plotze M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol. 2014;140:1947–1956. [PubMed]
    Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;160:321–330. [PubMed]
    Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma. 2012;53:632–634. [PubMed]
    Grey-Davies E, Bosworth JL, Boyd KD, et al. Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol. 2012;156:552–555. [PubMed]
    Lau IJ, Smith D, Aitchison R, et al. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Ann Hematol. 2015;94:643–649. [PubMed]
    Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012;119:4608–4613. [PMC free article] [PubMed]
    Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014;123:985–991. [PMC free article] [PubMed]
    Michael M, Bruns I, Bolke E, et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res. 2010;15:13–19. [PMC free article] [PubMed]
    Pönisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol. 2008;143:191–200. [PubMed]
    Pönisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol. 2013;139:499–508. [PubMed]
    Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157. [PMC free article] [PubMed]
    Vij R. Treatment-related adverse events in patients with relapsed/refractory multiple myeloma. Oncology (Williston Park) 2011;25(Suppl. 2):45–55. [PubMed]
    Grzasko N, Morawska M, Hus M. Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk. 2014;15:187–198. [PubMed]
    Pönisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol. 2012;138:1405–1412. [PubMed]
    Pönisch W, Moll B, Bourgeois M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol. 2013;139:1937–1946. [PubMed]
    Mark TM, Reid W, Niesvizky R, et al. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013;19:831–837. [PMC free article] [PubMed]
    Burotto M, Stetler-Stevenson M, Arons E, et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res. 2013;19:6313–6321. [PMC free article] [PubMed]
    Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29:3389–3395. [PubMed]
    Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205. [PubMed]
    Cheson BD, Kroll ML. Bendamustine induced neurotoxicity. Clin Adv Hematol Oncol. 2009;7:743–746. [PubMed]
    Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol. 2010;66:1039–1049. [PMC free article] [PubMed]
    Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with Rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood. 2009;114:205.
    Dubbelman AC, Rosing H, Darwish M, et al. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Drugs R D. 2013;13:17–28. [PMC free article] [PubMed]
    Preiss R, Teichert J, Athmani A, et al. 2010.
    http://www.medicines.ie/medicine/14828/SPC/Levact+25mg+and+100+mg++powder+for+concentrate+for+solution+for+infusion/
    Goede V, Fischer K, Busch R, et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia. 2013;27:1172–1174. [PubMed]
    Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223. [PMC free article] [PubMed]
    O’Brien S, Furman RR, Coutre SE. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58. [PMC free article] [PubMed]
    Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007. [PMC free article] [PubMed]

 

Заинтересовала статья?

Введен недействительный тип данных

Введен недействительный тип данных